跳转至

听觉扭曲

◀返回

听觉扭曲（Auditory distortion）就是体验到听到的声音在呈现和结构上发生了改变哦。

这些失真可以表现为多种风格，但通常采取回声或杂音的形式，随着每个声音的尾声升起，并伴随着速度和音调的波动变化呢。这种情况可能会加剧，直到声音持续伴随着不断的混响，通常会让原来的声音完全无法辨认。但是嘛，如果噪声源停止或改变，它通常会很快重置到基础水平并重新开始。

这种效应的体验可以分解为三个不同的强度等级。下面是对它们的描述和记录哦：

  1. 轻微 - 在最低的强度水平下，听觉扭曲包括外部环境中噪音的微妙和自发的混响、回声效应以及音调变化。它们是短暂的、强度低的，很容易被忽略呢。
  2. 明显 - 在这个水平上，听觉扭曲包括明显的、自发的的回声效应和归因于外部环境中噪音的音调变化。它们很长，拖得很慢，而且响亮到难以忽视哦。
  3. 完全包围 - 在最高水平上，听觉扭曲变得持续且无法忽视。由此产生的改变的复杂性很快就会让原来的声音变得难以理解。

听觉扭曲通常伴随着其他同时发生的效应，比如听觉幻觉、听觉敏锐度抑制和听觉敏锐度增强。它们最常在迷幻剂类化合物（如LSD、5-MeO-DiPT和DMT）的中等剂量影响下被诱发。不过呢，它们也可能较少见地在解离剂（如氯胺酮、PCP和氧化亚氮）的影响下发生。

例子

Both.ogg

上面的音频片段演示了在经历第3级听觉扭曲时听讲座可能听起来是什么样子的喵。

Distorted_Forest.ogg

这个音频片段表示森林环境中的第3级音频失真哦。

体验报告

在我们的体验索引中，描述这种效应的轶事报告包括：

  • Experience: 36mg 4-AcO-DiPT - Truly, one for the psychedelic animals among us
  • Experience: 5-EAPB (60mg) + 2-FMA (20mg) + 4-AcO-DMT (10mg) - Emotional catharsis_%2B_2-FMA_(20mg)%2B_4-AcO-DMT(10mg)_-_Emotional_catharsis)
  • Experience:1000 Morning Glory seeds - Rediscovering the Self
  • Experience:100ug 1P-LSD - A Fear and loathing into Bliss
  • Experience:225mg Pregabalin +Cannabis -Bliss and Serenity; a hedonistic evening
  • Experience:250mg MDA / 250mg MDMA - unnecessarily large dosage
  • Experience:300µg ETH-LAD - Turned Inside Out
  • Experience:300µg LSD - Togetherness and the Silent Dusk
  • Experience:3g mimosa / 2g syrian rue - I was the Universe's prophet
  • Experience:40mg - Brothermind and the Forest's Hand
  • Experience:4x 200ug tabs - You do not need to understand
  • Experience:5.3g psilocybe cubensis - Dimensional Circumstance and the Fabric of Understanding
  • Experience:5g Mushrooms - Failed attempt at a Terence Mckenna style trip.
  • Experience:6g mimosa / 2.5 g syrian rue - Best cake I've had for a while
  • Experience:LSD (400ug, Oral) - An afternoon in "a" garden_-An_afternoon_in%22a%22_garden)
  • Experience:Mushrooms and Snuff Films -- Trip Report (3.5 grams))
  • Experience:Unknown Dose DOC (Insufflated) - Overdosing and Terifying Ego Death_-_Overdosing_and_Terifying_Ego_Death)
  • Experience:~150mg MDA(oral) - a case of mistaken identity_-_a_case_of_mistaken_identity)

另见

参考文献

  1. ↑ 1.0 1.1 Carbonaro, T. M., Forster, M. J., Gatch, M. B. (March 2013). "Discriminative stimulus effects of N,N-diisopropyltryptamine". Psychopharmacology. 226 (2): 241–246. doi:10.1007/s00213-012-2891-x. ISSN 0033-3158.
  2. ↑ 2.0 2.1 2.2 Juszczak, G. R., Swiergiel, A. H. (1 January 2013). "Recreational Use of D-Lysergamide from the Seeds of Argyreia Nervosa , Ipomoea Tricolor, Ipomoea Violacea, and Ipomoea Purpurea in Poland". Journal of Psychoactive Drugs. 45 (1): 79–93. doi:10.1080/02791072.2013.763570. ISSN 0279-1072.
  3. ↑ Mehta, U. M., Naveen Kumar, C., Venkatasubramanian, G., Thirthalli, J. (January 2017). "Multimodal Sensory Distortions in Postpartum Exacerbation of Schizophrenia". Clinical Schizophrenia & Related Psychoses. 10 (4): 222–224. doi:10.3371/CSRP.MEKU.112013. ISSN 1935-1232.
  4. ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 Weinel, J. (3 March 2016). "Entoptic Phenomena in Audio : Categories of Psychedelic Electroacoustic Composition". Contemporary Music Review. 35 (2): 202–223. doi:10.1080/07494467.2016.1221633. ISSN 0749-4467.
  5. ↑ 5.0 5.1 5.2 5.3 Strassman, R. (2001). DMT: the spirit molecule: a doctor’s revolutionary research into the biology of near-death and mystical experiences. Park Street Press. ISBN 9780892819270.
  6. ↑ 6.0 6.1 6.2 6.3 N. Stanciu, C., M. Penders, T. (1 June 2016). "Hallucinogen Persistent Perception Disorder Induced by New Psychoactive Substituted Phenethylamines; A Review with Illustrative Case". Current Psychiatry Reviews. 12 (2): 221–223.
  7. ↑ 7.0 7.1 Espiard, M.-L., Lecardeur, L., Abadie, P., Halbecq, I., Dollfus, S. (August 2005). "Hallucinogen persisting perception disorder after psilocybin consumption: a case study". European Psychiatry. 20 (5–6): 458–460. doi:10.1016/j.eurpsy.2005.04.008. ISSN 0924-9338.
  8. ↑ 8.0 8.1 Shulgin, A., Shulgin, A. (1997). TIHKAL: The Continuation. Transform Press.
  9. ↑ Strassman, R. J., Qualls, C. R., Berg, L. M. (May 1996). "Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans". Biological Psychiatry. 39 (9): 784–795. doi:10.1016/0006-3223(95)00200-6. ISSN 0006-3223.
  10. ↑ Meatherall, R., Sharma, P. (1 July 2003). "Foxy, a Designer Tryptamine Hallucinogen*". Journal of Analytical Toxicology. 27 (5): 313–317. doi:10.1093/jat/27.5.313. ISSN 1945-2403.
  11. ↑ Mowry, M., Mosher, M., Briner, W. (September 2003). "Acute Physiologic and Chronic Histologic Changes in Rats and Mice Exposed to the Unique Hallucinogen Salvinorin A". Journal of Psychoactive Drugs. 35 (3): 379–382. doi:10.1080/02791072.2003.10400021. ISSN 0279-1072.
  12. ↑ Leake, C. D. (21 February 1972). "Hallucinogenic Drug Reaction—MDA". JAMA: The Journal of the American Medical Association. 219 (8): 1069. doi:10.1001/jama.1972.03190340073029. ISSN 0098-7484.
  13. ↑ Hillhouse, T. M., Porter, J. H., Negus, S. S. (1 May 2014). "Reply to: Rapid antidepressant effects and abuse liability of ketamine". Psychopharmacology. 231 (9): 2043–2044. doi:10.1007/s00213-014-3544-z. ISSN 1432-2072.
  14. ↑ Oye, I., Paulsen, O., Maurset, A. (March 1992). "Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors". The Journal of Pharmacology and Experimental Therapeutics. 260 (3): 1209–1213. ISSN 0022-3565.